Latest Theratechnologies Inc (THERF) Headlines
Theratechnologies Announces Financial Results for Fiscal Year 2013
Marketwire - Thu Feb 27, 6:02AM CST
Theratechnologies Inc. (Theratechnologies) (TSX: TH) today announced its financial results for the year ended November 30, 2013.
Theratechnologies to Announce Financial Results for Fiscal Year 2013
Marketwire - Tue Feb 25, 4:01PM CST
Theratechnologies Inc. (TSX: TH) (Theratechnologies) announced today that it will issue its financial results for the fiscal year ended November 30, 2013, on Thursday, February 27, 2014, before markets open.
Theratechnologies Inc.: Short Supply of EGRIFTA(R) Announced
Marketwire - Fri Feb 14, 5:01AM CST
Theratechnologies Inc. (TSX: TH) announced today that it expects current inventory of EGRIFTA(R) (tesamorelin for injection) to be depleted in the coming weeks due to a combination of manufacturing delays and issues observed during the production of new batches of EGRIFTA(R). The depletion of the inventory will result in a shortage of EGRIFTA(R) and an eventual stock-out. EMD Serono, Inc. has notified the United States Food and Drug Administration about this product shortage.
IIROC Trade Resumption - Theratechnologies Inc.
Newsfile Corp - Fri Dec 13, 7:46AM CST
Trading resumes in:
IIROC Trade Halt - Theratechnologies Inc.
Newsfile Corp - Fri Dec 13, 7:44AM CST
The following issues have been halted by IIROC:
Theratechnologies Regains U.S. Marketing Rights to EGRIFTA(R)
Marketwire - Fri Dec 13, 7:30AM CST
Theratechnologies Inc. (TSX: TH) today announced that it has reached an agreement with EMD Serono to regain all rights under the current collaboration and licensing agreement entered into in 2008 with EMD Serono, including commercialization rights for EGRIFTA(R) (tesamorelin for injection) in the United States.
Theratechnologies Resumes Shipment of Tesamorelin to EMD Serono
Marketwire - Tue Dec 03, 3:54PM CST
Theratechnologies Inc. (TSX: TH) is pleased to announce that it has resumed shipment of EGRIFTA(TM) (tesamorelin for injection) to EMD Serono in the United States today.
Mild Cognitive Impairment - Pipeline Review, H2 2013
M2 - Mon Nov 25, 2:26AM CST
Research and Markets (http://www.researchandmarkets.com/research/5vvwc8/mild_cognitive) has announced the addition of the "Mild Cognitive Impairment - Pipeline Review, H2 2013" report to their offering. 'Mild Cognitive Impairment - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Mild Cognitive Impairment, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Mild Cognitive Impairment. Scope - A snapshot of the global therapeutic scenario for Mild Cognitive Impairment. - A review of the Mild Cognitive Impairment products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Mild Cognitive Impairment pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Mild Cognitive Impairment. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Mild Cognitive Impairment pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned Boehringer Ingelheim GmbH Takeda Pharmaceutical Company Limited Chiesi Farmaceutici SpA Pfizer Inc. Paladin Labs Inc. Theratechnologies Inc. Suven Life Sciences Ltd. QR Pharma, Inc. For more information visit http://www.researchandmarkets.com/research/5v..._cognitive About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Jubilant HollisterStier Notifies Theratechnologies of Labour Disruption
Marketwire - Wed Nov 13, 4:30PM CST
Theratechnologies Inc. (TSX: TH) today announced that it has been informed by Jubilant HollisterStier (Jubilant), the third-party contract manufacturer for tesamorelin, that a strike has been initiated by employees working at its manufacturing site in Montreal, Canada.
Theratechnologies Inc.: Health Canada Agrees to Reconsider Tesamorelin
Marketwire - Fri Nov 01, 10:47AM CDT
Theratechnologies Inc. (TSX: TH) today announced that Health Canada has agreed to resume review of the tesamorelin New Drug Submission (NDS) and has rescinded the notice of non-compliance/withdrawal (NON/w) it issued in March 2013.
Abdominal Obesity - Pipeline Review, H2 2013
M2 - Fri Oct 11, 8:55AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rm9rd6/abdominal_obesity) has announced the addition of the "Abdominal Obesity - Pipeline Review, H2 2013" report to their offering. 'Abdominal Obesity - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Abdominal Obesity, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Abdominal Obesity. Scope - A snapshot of the global therapeutic scenario for Abdominal Obesity. - A review of the Abdominal Obesity products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Abdominal Obesity pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Abdominal Obesity. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Abdominal Obesity pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned Theratechnologies Inc. Aileron Therapeutics, Inc. Lithera, Inc. For more information visit http://www.researchandmarkets.com/research/rm...al_obesity About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Theratechnologies Announces Financial Results for Third Quarter of 2013
Marketwire - Thu Oct 10, 6:01AM CDT
Theratechnologies Inc. (Theratechnologies) (TSX: TH) today announced its financial results for the third quarter ended August 31, 2013.
Theratechnologies Announces Financial Results for Fiscal Year 2013
Marketwire - Thu Feb 27, 6:02AM CST
Theratechnologies Inc. (Theratechnologies) (TSX: TH) today announced its financial results for the year ended November 30, 2013.
Theratechnologies to Announce Financial Results for Fiscal Year 2013
Marketwire - Tue Feb 25, 4:01PM CST
Theratechnologies Inc. (TSX: TH) (Theratechnologies) announced today that it will issue its financial results for the fiscal year ended November 30, 2013, on Thursday, February 27, 2014, before markets open.
Theratechnologies Inc.: Short Supply of EGRIFTA(R) Announced
Marketwire - Fri Feb 14, 5:01AM CST
Theratechnologies Inc. (TSX: TH) announced today that it expects current inventory of EGRIFTA(R) (tesamorelin for injection) to be depleted in the coming weeks due to a combination of manufacturing delays and issues observed during the production of new batches of EGRIFTA(R). The depletion of the inventory will result in a shortage of EGRIFTA(R) and an eventual stock-out. EMD Serono, Inc. has notified the United States Food and Drug Administration about this product shortage.
IIROC Trade Resumption - Theratechnologies Inc.
Newsfile Corp - Fri Dec 13, 7:46AM CST
Trading resumes in:
IIROC Trade Halt - Theratechnologies Inc.
Newsfile Corp - Fri Dec 13, 7:44AM CST
The following issues have been halted by IIROC:
Theratechnologies Regains U.S. Marketing Rights to EGRIFTA(R)
Marketwire - Fri Dec 13, 7:30AM CST
Theratechnologies Inc. (TSX: TH) today announced that it has reached an agreement with EMD Serono to regain all rights under the current collaboration and licensing agreement entered into in 2008 with EMD Serono, including commercialization rights for EGRIFTA(R) (tesamorelin for injection) in the United States.
Theratechnologies Resumes Shipment of Tesamorelin to EMD Serono
Marketwire - Tue Dec 03, 3:54PM CST
Theratechnologies Inc. (TSX: TH) is pleased to announce that it has resumed shipment of EGRIFTA(TM) (tesamorelin for injection) to EMD Serono in the United States today.
Mild Cognitive Impairment - Pipeline Review, H2 2013
M2 - Mon Nov 25, 2:26AM CST
Research and Markets (http://www.researchandmarkets.com/research/5vvwc8/mild_cognitive) has announced the addition of the "Mild Cognitive Impairment - Pipeline Review, H2 2013" report to their offering. 'Mild Cognitive Impairment - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Mild Cognitive Impairment, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Mild Cognitive Impairment. Scope - A snapshot of the global therapeutic scenario for Mild Cognitive Impairment. - A review of the Mild Cognitive Impairment products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Mild Cognitive Impairment pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Mild Cognitive Impairment. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Mild Cognitive Impairment pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned Boehringer Ingelheim GmbH Takeda Pharmaceutical Company Limited Chiesi Farmaceutici SpA Pfizer Inc. Paladin Labs Inc. Theratechnologies Inc. Suven Life Sciences Ltd. QR Pharma, Inc. For more information visit http://www.researchandmarkets.com/research/5v..._cognitive About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Jubilant HollisterStier Notifies Theratechnologies of Labour Disruption
Marketwire - Wed Nov 13, 4:30PM CST
Theratechnologies Inc. (TSX: TH) today announced that it has been informed by Jubilant HollisterStier (Jubilant), the third-party contract manufacturer for tesamorelin, that a strike has been initiated by employees working at its manufacturing site in Montreal, Canada.
Theratechnologies Inc.: Health Canada Agrees to Reconsider Tesamorelin
Marketwire - Fri Nov 01, 10:47AM CDT
Theratechnologies Inc. (TSX: TH) today announced that Health Canada has agreed to resume review of the tesamorelin New Drug Submission (NDS) and has rescinded the notice of non-compliance/withdrawal (NON/w) it issued in March 2013.
Abdominal Obesity - Pipeline Review, H2 2013
M2 - Fri Oct 11, 8:55AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rm9rd6/abdominal_obesity) has announced the addition of the "Abdominal Obesity - Pipeline Review, H2 2013" report to their offering. 'Abdominal Obesity - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Abdominal Obesity, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Abdominal Obesity. Scope - A snapshot of the global therapeutic scenario for Abdominal Obesity. - A review of the Abdominal Obesity products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Abdominal Obesity pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Abdominal Obesity. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Abdominal Obesity pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned Theratechnologies Inc. Aileron Therapeutics, Inc. Lithera, Inc. For more information visit http://www.researchandmarkets.com/research/rm...al_obesity About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Theratechnologies Announces Financial Results for Third Quarter of 2013
Marketwire - Thu Oct 10, 6:01AM CDT
Theratechnologies Inc. (Theratechnologies) (TSX: TH) today announced its financial results for the third quarter ended August 31, 2013.
